[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX345697B - Formulaciones de rifaximina y usos de las mismas. - Google Patents

Formulaciones de rifaximina y usos de las mismas.

Info

Publication number
MX345697B
MX345697B MX2013000522A MX2013000522A MX345697B MX 345697 B MX345697 B MX 345697B MX 2013000522 A MX2013000522 A MX 2013000522A MX 2013000522 A MX2013000522 A MX 2013000522A MX 345697 B MX345697 B MX 345697B
Authority
MX
Mexico
Prior art keywords
rifaximin
formulations
methods
relates
present
Prior art date
Application number
MX2013000522A
Other languages
English (en)
Other versions
MX2013000522A (es
Inventor
Selbo Jon
Teng Jing
A Kabir Mohammed
Golden Pam
Original Assignee
Salix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Ltd filed Critical Salix Pharmaceuticals Ltd
Publication of MX2013000522A publication Critical patent/MX2013000522A/es
Publication of MX345697B publication Critical patent/MX345697B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La presente invención se refiere a nuevas formas de rifaximina que comprenden dispersiones sólidas de rifaximina, métodos para hacer las mismas y a su uso en preparaciones medicinales y métodos terapéuticos.
MX2013000522A 2010-07-12 2011-07-12 Formulaciones de rifaximina y usos de las mismas. MX345697B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36360910P 2010-07-12 2010-07-12
US41905610P 2010-12-02 2010-12-02
PCT/US2011/043769 WO2012009388A1 (en) 2010-07-12 2011-07-12 Formulations of rifaximin and uses thereof

Publications (2)

Publication Number Publication Date
MX2013000522A MX2013000522A (es) 2013-05-01
MX345697B true MX345697B (es) 2017-02-13

Family

ID=45469785

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013000522A MX345697B (es) 2010-07-12 2011-07-12 Formulaciones de rifaximina y usos de las mismas.

Country Status (26)

Country Link
US (4) US20120077835A1 (es)
EP (2) EP3750526A1 (es)
JP (1) JP5943915B2 (es)
KR (1) KR101887004B1 (es)
CN (1) CN103228662B (es)
AU (1) AU2011279261B2 (es)
BR (1) BR112013000802B1 (es)
CA (1) CA2804635C (es)
CR (1) CR20130033A (es)
DK (1) DK2593463T3 (es)
EA (1) EA033370B1 (es)
ES (1) ES2801678T3 (es)
GE (1) GEP20227342B (es)
HU (1) HUE049986T2 (es)
IL (1) IL223725B (es)
LT (1) LT2593463T (es)
MX (1) MX345697B (es)
MY (1) MY165086A (es)
NZ (1) NZ605232A (es)
PL (1) PL2593463T3 (es)
PT (1) PT2593463T (es)
SG (2) SG186981A1 (es)
SI (1) SI2593463T1 (es)
TN (1) TN2012000611A1 (es)
WO (2) WO2012009387A1 (es)
ZA (1) ZA201300193B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1698630T1 (sl) 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
US9018684B2 (en) 2009-11-23 2015-04-28 California Institute Of Technology Chemical sensing and/or measuring devices and methods
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
CA2854380A1 (en) * 2011-11-02 2013-05-10 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (ibs) and infections
JP2015509105A (ja) * 2012-01-25 2015-03-26 サリックス ファーマスーティカルズ，リミテッド リファキシミン誘導体及びその使用
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
EP2757135B1 (en) 2013-01-18 2017-11-29 3M Innovative Properties Company Method of bonding parts to a vehicle by an acrylic foam tape
WO2015069305A1 (en) * 2013-11-08 2015-05-14 Tyrx, Inc. Antimicrobial compositions and methods for preventing infection in surgical incision sites
EP3140313B1 (en) 2014-05-04 2020-02-26 Salix Pharmaceuticals, Inc. Ibs microbiota and uses thereof
PL3546464T3 (pl) 2014-05-12 2020-11-02 Alfasigma S.P.A. Sposób wytwarzania i zastosowanie postaci krystalicznej Tau rifaksyminy solwatowanej z DEGME
WO2016198983A1 (en) 2015-06-09 2016-12-15 Bend Research Inc. Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
JP7024248B2 (ja) * 2016-09-01 2022-02-24 大正製薬株式会社 固形製剤
EP4137132A1 (en) 2016-09-30 2023-02-22 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
US10792249B2 (en) * 2017-07-24 2020-10-06 Acryspharm Llc High drug loading pharmaceutical compositions
CN109453165B (zh) * 2018-10-16 2021-02-05 丹诺医药(苏州）有限公司 一种利福霉素-硝基咪唑偶联分子的固体分散体及其应用
CN109453166B (zh) * 2018-10-16 2021-03-12 丹诺医药(苏州）有限公司 一种利福霉素-喹嗪酮偶联分子的固体分散体及其应用
US20220184044A1 (en) * 2019-03-22 2022-06-16 New York Medical College Use of rifaximin on circulating aged neutrophils in sickle cell disease
WO2021058656A1 (en) 2019-09-24 2021-04-01 Bausch Health Ireland Limited Rifaximin liquid formulations
US20230141118A1 (en) * 2020-04-13 2023-05-11 Bausch Health Ireland Limited Methods of using solid dispersions of rifaximin for the treatment of sickle cell disease
EP4171520A1 (en) 2020-06-26 2023-05-03 Bausch Health Ireland Limited Targeted release rifaximin compositions
US20230398102A1 (en) 2020-10-29 2023-12-14 Bausch Health Ireland Limited Rifaximin liquid formulations for use inthe treatment of sickle cell disease
CN114366717B (zh) * 2022-01-11 2023-06-09 四川农业大学 一种基于egcg纳米粒的肠溶固体分散体颗粒、制备方法及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
IT1320176B1 (it) 2000-12-22 2003-11-26 Nicox Sa Dispersioni solide di principi attivi nitrati.
AU2002304387A1 (en) * 2001-06-22 2003-01-08 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
BRPI0418330A (pt) * 2003-12-31 2007-05-02 Pfizer Prod Inc composições sólidas de drogas de solubilidade baixa e poloxámeros
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
SI1698630T1 (sl) 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
US20080095754A1 (en) * 2006-10-18 2008-04-24 Burke Susan E Ophthalmic compositions comprising diglycine
WO2009008005A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
SI2011486T1 (sl) * 2007-07-06 2012-10-30 Lupin Ltd Farmacevtski sestavki rifaksimina
KR100903618B1 (ko) * 2007-10-30 2009-06-18 삼성에스디아이 주식회사 플라즈마 디스플레이 패널
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
UA113275C2 (xx) * 2008-02-25 2017-01-10 ζ-ФОРМА РИФАКСИМІНУ І ЇЇ ЗАСТОСУВАННЯ
EP2252148B1 (en) * 2008-02-26 2019-03-20 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome
EP2105130A1 (de) * 2008-03-25 2009-09-30 Ratiopharm GmbH Pharmazeutische Formulierung und Verfahren zu deren Herstellung
NZ593757A (en) * 2008-12-10 2013-03-28 Cipla Ltd Rifaximin complexes
CN102665693A (zh) 2009-10-27 2012-09-12 鲁平有限公司 利福昔明固体分散体
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
WO2011112558A2 (en) * 2010-03-10 2011-09-15 Abbott Laboratories Solid compositions

Also Published As

Publication number Publication date
SI2593463T1 (sl) 2020-10-30
US20200397904A1 (en) 2020-12-24
KR101887004B1 (ko) 2018-08-09
SG10201505484RA (en) 2015-09-29
WO2012009388A1 (en) 2012-01-19
HUE049986T2 (hu) 2020-11-30
EP2593463A4 (en) 2014-04-23
LT2593463T (lt) 2020-08-25
CR20130033A (es) 2013-04-29
PT2593463T (pt) 2020-09-17
SG186981A1 (en) 2013-02-28
US20150133482A1 (en) 2015-05-14
CA2804635A1 (en) 2012-01-19
JP2013532633A (ja) 2013-08-19
AU2011279261B2 (en) 2016-03-31
TN2012000611A1 (en) 2014-04-01
BR112013000802B1 (pt) 2021-08-31
US9737610B2 (en) 2017-08-22
PL2593463T3 (pl) 2020-11-02
JP5943915B2 (ja) 2016-07-05
NZ605232A (en) 2015-09-25
US20120077835A1 (en) 2012-03-29
MX2013000522A (es) 2013-05-01
EA201370018A1 (ru) 2013-09-30
CA2804635C (en) 2019-09-10
ZA201300193B (en) 2019-07-31
MY165086A (en) 2018-02-28
EA033370B1 (ru) 2019-10-31
CN103228662B (zh) 2016-08-10
DK2593463T3 (da) 2020-08-10
ES2801678T3 (es) 2021-01-12
GEP20227342B (en) 2022-01-25
KR20130098300A (ko) 2013-09-04
EP2593463B1 (en) 2020-05-06
IL223725B (en) 2020-03-31
US20170333562A1 (en) 2017-11-23
AU2011279261A1 (en) 2013-01-17
EP2593463A1 (en) 2013-05-22
WO2012009387A1 (en) 2012-01-19
EP3750526A1 (en) 2020-12-16
BR112013000802A2 (pt) 2016-05-24
CN103228662A (zh) 2013-07-31

Similar Documents

Publication Publication Date Title
TN2012000611A1 (en) Formulations of rifaximin and uses thereof
TN2012000414A1 (en) Forms of rifaximin and uses thereof
HK1252481A1 (zh) 疏水性治療劑的製劑、其製備方法及應用
WO2012030993A3 (en) Skin compositions and methods of use thereof
TN2012000533A1 (en) New forms of rifaximin and uses thereof
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
UA109464C2 (uk) Спірооксіндольні антагоністи mdm2
MX2013001677A (es) Formulaciones estables de linaclotida.
MY191669A (en) Pyrazolyl quinoxaline kinase inihibitors
MX349004B (es) Nuevos compuestos.
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
GB201209613D0 (en) New compounds
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
MX366899B (es) Nuevos compuestos.
WO2012047951A3 (en) Human lung stem cells and uses thereof
TN2012000488A1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MX2012010127A (es) Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos.
WO2011107866A3 (en) Silyl-derivatives of polysaccharides
MX2023003000A (es) Formulaciones de liberacion modificada de viloxacina.
IN2014DN10134A (es)
WO2014096086A3 (fr) Utilisation de microorganismes probiotiques comme agent favorisant la synthèse de mélanine
UA111824C2 (uk) Лікарські форми рифаксиміну і їх застосування
WO2014096084A3 (fr) Utilisation de microorganismes probiotiques comme agent favorisant la synthèse de mélanine
TN2010000377A1 (en) Forms of rifaximin and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration